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1. ABSTRACT 
 
Male factor infertility accounts for about half the 
cases of couple infertility and in around 50% of cases its 
etiology remains unknown. Molecular genetic techniques 
have unveiled a number of etiopathogenetic factors, 
including microdeletions of the Yq. Y chromosome 
microdeletions removing the AZoospermia Factor (AZF) 
regions are the most frequent molecular genetic causes of 
oligo/azoospermia. The intense effort of many laboratories 
contributed to a better understanding of the clinical 
significance of this genetic anomaly and to the 
identification of fertility candidate genes in the AZF 
regions. Important progress has been made on the structure 
of the Y chromosome and the mechanism of deletion. 
Studies aimed to define a predisposing genetic background 
for Yq deletions were not successful, perhaps due to the 
low number of patients analyzed so far. The screening for 
Yq deletions became a routine diagnostic test that provides 
an etiology for spermatogenic disturbances, and assess in 
the prognosis for testicular sperm retrieval according to the 
type of deletion. Assisted reproductive techniques represent 
an efficient symptomatic therapy for men bearing Y 
microdeletions, however, this genetic defect is transmitted 
to the male offsprings, affecting their fertility. Future 
studies should focus on understanding the biological 
function of AZF genes which is an essential step for the 
development of more appropriate and knowledge-based 
therapies. 
  
 
 
 
 
 
2. INTRODUCTION 
 
The first review on Y chromosome and male 
infertility appeared in the Frontiers in Bioscience in 1999 
(1), 3 years after the molecular definition of the three AZF 
regions (2). At that time, there were already about 20 
publications that described large scale screening for Yq 
deletions in infertile men. The clinical definition of patients 
and the markers used for the screening were heterogeneous 
and consequently, many important clinical questions were 
still unresolved. At that time, it was still unclear what the 
real frequency of the AZF deletions was and if there were 
any ethnic or geographic differences or any predisposing Y 
background. Concerns were raised about the existence of a 
genotype-phenotype correlation and about the specificity of 
AZF deletions in spermatogenic failure.  
 
However, despite controversies, we pointed out at 
that time that the diagnosis  of Yq deletions has an 
important clinical value since it provides the etiology of 
spermatogenic failure and enables one to avoid unnecessary 
medical or surgical treatments. Moreover, since a 
progressive decrease of sperm count over time was 
observed in these patients, we proposed sperm 
cryoconservation for both the patient and for his future son, 
as a preventive therapy. In the same year, the first EAA 
guidelines for Y chromosome deletion screening was also 
published which has clearly indicated the need for using a 
reliable set of markers for routine analysis (3). At the time
Y chromosome and male infertility   
3050 
 
 
Figure 1. Schematic representation of the Y chromosome 
showing the 7 deletion intervals. The three AZF regions 
and the candidate AZF genes are indicated. 
PseudoAutosomial Region 1 and 2 (PAR1, PAR2); Yp: 
short arm of the Y chromosome; Yq: long arm of the Y. 
 
that the majority of the AZF genes were identified (4), we 
were confident that insights into the function of the AZF 
genes would have been achieved very soon.  
 
By the beginning of 2005, many of the above 
mentioned clinical questions were answered and thanks to 
the EAA guidelines and EAA/EMQN external quality 
control programme (5, 6) Yq testing has become more 
homogeneous and reliable in different laboratories. The 
complete Y sequence and gene /transcript content was 
published and the mechanism by which AZF deletions take 
place was fully understood (7). Recently, new deletion 
types with yet uncertain clinical meaning have also been 
reported opening a new area of research in this field (8, 9 
and references therein). 
 
Unfortunately, our knowledge concerning the 
biological function of the AZF genes has only slowly  
progressed during the last 6 years and the time for a 
knowledge-based aetiological therapy seems to be still very 
far away.   An updated analysis of the available data on the 
Y chromosome and male infertility including  both clinical 
and basic research is the subject of the present review.   
 
3. Y CHROMOSOME STRUCTURE 
 
The Y chromosome comprises only 2-3% of the 
haploid genome. It is an acrocentric chromosome and 
consequently contains a short arm (Yp) and long arm (Yq), 
demarcated by a centromeric region essential for 
chromosome segregation (Figure 1). The human Y 
chromosome is classically divided into two functionally 
distinct regions: i) the pseudoautosomal regions (PAR1 and 
PAR2), which are homologous with X chromosome 
sequences and are responsible for correct pairing between 
the two sex chromosomes during male meiosis; ii) the male 
specific region Y (MSY), previously called the “Non-
recombining region Y” (NRY), in which, in certain parts, 
instead of classical recombination “intrachromosomal gene 
conversion” (non-reciprocal transfer) takes place (10). 
Thanks to the presence of this conversion–based system of 
gene copy “correction”, a certain number of Y genes have 
been preserved from the gradual accumulation of 
deleterious mutations ensuring their continuity in time 
(7,10). This region comprises 95% of the length of the 
chromosome. 
 
The extent of the MSY region is roughly 63Mb, 
but only 23Mb are transcriptionally active (euchromatic 
portion). The heterochromatic region comprises distal Yq. 
This region is polymorphic (variation in length) within 
males, constituting almost half the chromosome in some 
men while being undetectable in some others. This part of 
the chromosome is assumed to be genetically inert and it is 
mainly composed of two highly repetitive sequences 
families, DYZ1 and DYZ2, containing about 5000 and 
2000 copies of each respectively.  
 
The euchromatic region contains three classes of 
sequences, named by Page and collegues X-transposed, X-
degenerate and ampliconic (7). The X transposed sequences 
are 99% identical to DNA sequences in Xq21 and derive 
from a massive X to Y transposition that occurred about 3-
4 million years ago. These sequences contain the highest 
density of repeats (interspersed repeat elements) and only 
two genes with homologues in the Xp21. The X-degenerate 
segments are relatively rich of single copy gene or 
pseudogene homologues of X linked genes. The third class 
of sequences, ampliconic segments, are composed by long 
MSY specific repeat units named “amplicons” which show 
as much as 99,9% of intrachromosomal identity. These 
segments exhibit the highest density of genes, both coding 
and non-coding, among the three sequence classes. 
 
The MSY euchromatin contains a total of 156 
transcriptions units with 78 protein coding units and 78 
putative non coding units (7). The protein coding units are 
the product of 27 genes, 12 of which are expressed 
ubiquitously and 11 are exclusively, or predominantly, 
expressed in testes. All 12 ubiquitously expressed genes of 
the MSY reside in the so called X-degenerate sequence 
whereas the majority of genes with testis specific 
expression are located in the ampliconic segments. 
 
The majority of the MSY genes are involved in 
male specific functions, such as male sex determination 
(SRY) and spermatogenesis (i.e. genes of the AZoospermia 
Factor regions of the long arm of the Y chromosome). 
Consequently mutations/deletions of these genes lead to 
sex reversal or spermatogenic failure (1, 12). In addition, 
loss or rearrangements of the Y are also associated to a
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Figure 2. Schematic representation of the mechanism of AZF deletions. Boxes with motifs represent repeated homologous 
sequences situated at the border of recurrently deleted regions on the Yq. AZFa deletions occur between two homologous 
retroviral sequences (HERV15q). AZFb* deletions partially overlap with the AZFc region and may take place between different 
palindromic sequences (P5, P4, P1). The classical AZFc deletion occurs between two repeated sequences b2/b4 entirely situated 
in the AZFc region. The extent of the deleted segment is indicated in each type of AZF deletion (figure not in scale). 
 
number of other phenotypes, such as Turner stigmata (13), 
skeletal anomalies (14) and the development of a rare type 
of gonadal cancer (gonadoblastoma) (15). The MSY also 
contains genes with housekeeping cellular activities (7,16) 
and are probably involved in functions other than male 
reproduction. The same genes may be responsible of the 
sexual dimorphism observed for certain pathologies such as 
hypertension, autism etc. (for review see 17 and references 
therein). 
 
4. Yq DELETIONS AND SPERMATOGENESIS 
 
The first association between azoospermia 
(absence of spermatozoa in the ejaculate) and 
microscopically detectable deletions of the long arm of the 
Y chromosome has been demonstrated by Tiepolo and 
Zuffardi in 1976 (18). Since in 4 patients the deletion was 
de novo (their fathers were tested and found to carry intact 
Y chromosome) they proposed the existence of a 
spermatogenesis factor, the AZoospermia factor (AZF) 
encoded by a gene on distal Yq. Successively, the 
development of molecular genetic tools, firstly Y specific 
DNA probes (19) than sequence tagged sites (STS: short 
tracts of DNA that acts as a landmark to define position on 
a physical map) (20), permitted to narrow the extension of 
the AZF region. Using the above mentioned molecular 
tools the breakpoints of a large panel of infertile men 
displaying a cytogenetically visible abnormality in Yq lead 
to the construction of molecular interval maps. Many STS 
based screening have been undertaken in patients affected 
by azoo/severe oligozoospermia in order to define the AZF 
locus and isolate candidate genes for AZF. Vogt et al. (1) 
observed that Yq microdeletions follow a certain deletion 
pattern, with three recurrently deleted nonoverlapping 
subregions in proximal, middle and distal Yq11, designated 
AZFa, AZFb and AZFc, respectively. Only several years 
after the discovery of the three AZF regions, with the 
precise knowledge of the Y structure in Yq11, is became 
evident that the AZFb and AZFc regions are overlapping 
(10). New deletion patterns in the AZFb/AZFc regions 
have been proposed, however since data in the literature are 
based on markers which are unable to distinguish between 
these subtypes, it is more convenient to refer to the three 
“classical” deletion intervals. (Figure 1) 
 
5. GENES AND GENE FAMILIES OF THE AZF 
REGIONS 
 
5.1. AZFa region 
AZFa region is located in proximal Yq within 
deletion interval 5. In 1999, it was estimated that the region 
is between 1 and 3 Mb in size and contains four single copy 
genes, namely USP9Y (former DFFRY), DBY, UTY and 
TB4Y. After the discovery of the mechanism of the AZFa 
deletion formation (see below) it became evident that  its 
size is of 0,8 Mb (Figure 2) and contains only two single 
copy genes: USP9Y and DBY (21,22). The USP9Y protein 
is an ubiquitinyl hydrolase and belongs to the family C19 
(cystein peptidases) which are intracellular peptidases that 
remove ubiquitin molecules from polyubiquitinated 
peptides. It may therefore play an important role at the 
level of protein turnover by preventing degradation of 
proteins through the removal of conjugated ubiquitin. 
 
The DBY gene is predicted to encode an RNA 
helicase and thus is involved in RNA metabolism. Both 
genes are transcribed in multiple tissues and have a 
homologue on the X chromosome which escapes X 
inactivation. Protein expression analysis for the DBY gene 
allowed the identification of a translational control 
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mechanism. Vogt and coworkers reported (23) that despite 
the ubiquitous transcription of the DBY gene, its mRNA is 
translated specifically in the testis tissue and in particular in 
spermatogonia and pachytene spermatocytes.  
 
5.2. AZFb region 
Similar to the AZFa region, the discovery of the 
deletion mechanisms in concert with the fine definition of 
the Yq structure led to a fundamental change of our view 
concerning the extension of the AZFb region. It became 
clear that the classical AZFb region is partially overlapping 
with the AZFc region. Previously its estimated size was 
around 1-3 Mb, now we know that there are two possible 
recombination sites and the extent may vary from 6,2 to 
7,7Mb (10) (Figure 2).  
 
It contains genes which are present only in the 
AZFb region (HSFY, eIF-1Y, SMCY) and others which 
are shared with the AZFc region (one copy of BPY2 and 
CDY, two copies of DAZ). Moreover, two gene families 
with multiple copies on the Y have their active copies in 
the AZFb region: RBMY and PRY. More than 30 RBM 
genes and pseudogenes are spread over both arms of the 
Y chromosome (24-26). The AZFb region contains at 
least one functional RBM copy, located in the distal 
portion of this deletion interval (27) RBMY (RNA 
Binding Motif Y) is a testis specific splicing factor and 
it is homologous to RBMX on the X chromosome 
(hnRNPG) and to a functional retrogene on chromosome 
11 (11p15) hnRNPG-T. Both the X and the Y derived 
protein are highly expressed in mitotically active cells 
and thus may promote mitotic divisions in 
spermatogonia (28, for review see 29,30 and references 
therein). Beside spermatogonia, the RBMY protein is 
expressed also in the nuclei of spermatocytes and round 
spermatids.  
 
Two functional copies of the PRY gene are 
present in the AZFb region and encodes a protein 
phosphatase which is probably involved in apoptosis of 
defective spermatozoa (31). The expression pattern of this 
protein (in spermatids and spermatozoa) indicates a role in 
the post-meiotic phases of spermatogenesis.  
 
The HSFY (Heat Shock Factor Y) gene is 
situated in the palindromic sequence P4 in proximal 
AZFb and there are two copies. This gene encodes a 
novel heat shock protein which is specifically expressed 
in Sertoli and germ cells which exhibits a stage-
dependent translocation from the cytoplasm to the 
nucleus in spermatogenic cells during spermatogenesis 
(32). The gene has a homologue HSP2 on 6p22 which 
codes for a heat shock transcription factor. The eIF-1AY 
encodes a Y isoform of a eIF-1A, an essential 
translation initiation factor. eIF-1AY has been mapped 
to interval 5q and subsequently defined between sY127-
sY129 (33). This gene has an X homologue (eIF-1AX) 
which escapes inactivation. Both X and Y homologoues 
are ubiquitously expressed, with high level of 
expression in the testis (4). The biological function of 
SMCY is unknown but it encodes a male specific 
histocompatibility antigen (H-Y). 
5.3. AZFc region 
The region is 3,5 Mb and in analogy to the other 
two AZF regions it is delimited by two repeated sequences 
(b2 and b4) (Figure 2).  
 
 The first gene identified in the AZFc region is 
the DAZ gene (34). It is a multicopy gene with two copies 
situated in P2 (DAZ1/DAZ2) and two located 1.47 Mb 
distant  in the large P1 palindrome (DAZ3/DAZ4). The 
DAZ gene has been transposed and pruned (amplified) 
from chromosome 3 (3p25; DAZL1 locus) after divergence 
of the Old world monkey line of primates (35, 36). The 
structure of the 4 copies is variable especially in the 
number of exon 7 variants which is also known as the 
“DAZ-repeat” (37, 38). The DAZ gene family includes two 
autosomal homologues, DAZL on chromosome 3 and 
BOULE on chromosome 2 (39). The finding that the 
human DAZ transgene is able to partially rescue the 
spermatogenic failure of mice homozygous for a null allele 
of the Dazl gene (40) suggests a possible interplay between 
DAZL and DAZ in humans.  
 
All DAZ gene family members are encoding 
testis specific RNA binding proteins and thus are probably 
involved in the translational control of transcripts with 
spermatogenic function (for review see 41). Studies in flies 
demonstrate that the BOULE gene encodes a key factor of 
meiosis in male germ cells, regulating the expression of 
twine, a cdc25 phosphatase, which promotes progression 
through meiosis (42). In analogy, a translational control of 
CDC25 transcripts by BOULE has been reported also in 
human (43) and human BOULE transgene is able to rescue 
the meiotic block in boule mutant flies (44). DAZL and 
DAZ both interact with the DAZAP1 protein (Deleted in 
Azoospermia Associated Protein 1) which shuttles between 
the nucleus and the cytoplasm and may play a role in 
mRNA transport and/or localization (45). Expression 
analysis of the DAZ protein gave discordant results 
probably due to the use of different polyclonal DAZ-
antisera. In one study, DAZ mRNA was detected in early 
spermatids whereas the protein was observed in late 
spermatids and spermatozoa. (46). In an other study DAZ 
expression has been found in multiple cell compartments at 
multiple points in male germ cell development (47). In this 
study, human DAZ and human and mouse DAZL proteins 
were present in both the nuclei and cytoplasm of foetal 
gonocytes and in spermatogonial nuclei. Interestingly, the 
proteins relocate to the cytoplasm during male meiosis. 
Human DAZL protein (but not DAZ) persists in spermatids 
and even spermatozoa. These results would suggest that 
DAZ proteins may act during meiosis and much earlier, 
when spermatogonial stem cell populations are established. 
The observed protein-protein interaction between DAZL 
and Pumilio-2 (PUM2) also suggest an important role in 
fetal germ cell development (48). 
 
The CDY gene family has a similar origin like 
the DAZ gene i.e. it was retrotransposed from the CDYL 
locus on chromosome 6 (4). While the autosomal 
homologue is expressed ubiquitously, the CDY gene is 
specifically expressed in the testis. Four alternative spliced 
transcripts encoding three different protein isoforms have 
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been described (49). CDY are nuclear proteins observed in 
spermatids and show histone acetyl transferase activity 
with a strong preference for H4 (50). The Basic Protein Y 2 
(BPY2) gene is expressed exclusively in the testis. The 
BPY2 protein represent singleton without detectable 
sequence homologues. The analysis of the 3D protein 
structure predicted a possible role of this highly charged 
protein in DNA or RNA binding (51).  
 
A part from protein coding genes the AZF 
regions contain two gene families with unknown protein 
coding potential: i) the three members of the CYorf family 
(CYorf14, CYorf15A, CYorf15B) which are all expressed 
in multiple tissues and have homologues on the X (cXorf 
14, cXorf15, cXorf15). ii) The TTY (Testis Specific 
Transcription Y) family which are considered transcription 
units with no significant open reading frame. Members of 
this family are present also outside of the AZF regions on 
both the short and the long arm of the Y. 
 
For the moment it is not known whether all genes 
situated in the AZF regions are important for  
spermatogenesis. Since deletions occur in block- removing 
more than one gene- the role of a single AZF gene cannot 
be extrapolated from the deletion phenotype. To date only 
one confirmed gene specific deletion has been reported in 
the literature in which the breakpoint of the mutation has 
been defined (52). The associated phenotype i.e. 
hypospermatogenesis indicates that this gene, USP9Y, is 
probably not essential for the initiation and completion of 
spermatogenesis and it has probably  a role in enhancing 
the quality and efficiency of spermatogenesis. Other 
authors have also reported single gene deletions (DBY, 
USP9Y, HSF-Y) however these studies did not define the 
deletion breakpoints (53,54). Since polymorphisms, 
rearrangements may lead to false deletions these data await 
further confirmation. 
 
6. MECHANISM OF AZF DELETIONS 
 
The mechanism by which classical AZF deletions 
take place is through intrachromosomal recombination 
between homologous sequences (7, 55). The long arm is 
indeed composed of numerous Y specific repetitive 
sequence blocks (called “amplicons”). These amplicons are 
assembled in eight palindrome structures (P1-P8) and are 
highly symmetrical. The homologous amplicons mapped in 
the different palindrome arms revealed extensive 
homologies between 99.940 and 99.997%. The AZFb and 
AZFc deletions occur between palindromes whereas the 
AZFa deletion is the result of intrachromosomal 
recombination events between two repetitive specific 
HERV15 (Human Endogenous Retroviral #15) sequence 
blocks (22, 23). (Figure 2)   
 
7. AZF DELETIONS AND Y CHROMOSOME 
BACKGROUND 
 
Polymorphic markers on the MSY region define 
Y chromosome lineages (or haplogroups) which are 
monophyletic groups of Y chromosomes sharing allelic 
states at slowly mutating binary markers. Until now, more 
than 200 Y specific single nucleotide polymorphisms 
(SNPs) has been identified providing, together with a 
number of indels (insertions/deletions), a detailed and 
robust phylogenetic tree of Y chromosomal lineages 
(56,57). The absence of recombination on the MSY region 
makes that polymorphisms located in this region are in 
tight association with potential functional variations 
associated with Y-linked phenotypes.  
 
A predisposing Y background to AZF deletions 
has been hypothesized on the basis of a previous study 
reporting a Y haplogroup that is susceptible to aberrant 
X/Y exchange during male meiosis, leading to the XX male 
syndrome (58). Since the mechanism by which AZF 
microdeletions originate can be traced to intrachromosomal 
recombination between repetitive elements (22, 23, 55), 
sequence differences or different orientation of the repeated 
blocks may predispose or protect against specific type of 
deletions. An example is the polymorphic deletion of 
L1PA4 element which confers a higher homology between 
the two retroviral blocks in the flanking sequences of the 
AZFa region and thus may, in theory, facilitate homologous 
recombination. This deletion is considered as a 
polymorphism and reach high frequencies in populations 
from the Middle East. Similarly to AZFa region, there 
could be differing susceptibilities to the other AZF 
deletions depending on the Y chromosome structure. Men 
carrying Y chromosome microdeletions from Ireland, 
Scotland, Germany, Italy, Spain, Holland and Denmark 
were haplotyped and the haplotype distribution was then 
compared to infertile men without microdeletions (59) or 
compared to an unselected male control population (60). Y 
chromosome microdeletions were found to occur on 
different Y chromosome backgrounds and there was no 
significant difference between Y chromosome haplogroup 
distribution in the study and control groups. However, due 
to the relative rarity of AZFa deletions (5% of the total 
deletions), the number of this type of deletions included in 
both studies was small and, despite the apparent lack of 
association, the relationship between Y-chromosome 
background and microdeletion formation cannot be ruled out.  
 
Different Y chromosome backgrounds may also 
be responsible for the inter-individual variation in the 
phenotypic expression of a given AZF deletion such as the 
complete AZFc deletion which can be associated with both 
severe oligospermia or with the total absence of 
spermatogenic cells in the testis. Future clinical-molecular 
combined studies are needed to accredit this attractive 
hypothesis.  
 
A part from AZF deletions other Y related factors 
such as partial gene copy deletions of multicopy genes or 
rearrangements/inversions occurring in non coding 
sequences but with possible functional effects on gene 
expression may influence spermatogenesis. These type of 
alterations may segregate with certain Y backgrounds, 
therefore a role for Y chromosome background in 
determining spermatogenic potential has also been 
proposed. This hypothesis was confirmed in the Danish and 
Japanese population whereas not in others (for review see 
17 and references therein).  
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8. CLINICAL ASPECTS OF Yq DELETIONS 
 
The clinical significance of Yq deletions have 
been debated for long time mainly because of the large 
variability in deletion frequencies reported by different 
authors and because Yq deletions have also been reported 
in “fertile” men. Deletions which are clinically relevant 
remove partially or most frequently completely one or more 
AZF regions and they represent the most frequent 
molecular genetic cause of oligo/azoospermia.  
 
8.1. Y deletions are specific for spermatogenic 
disturbances 
In 12 men out of 2295 fertile controls, small 
deletions outside the DAZ region have been reported (for 
review see 61 and references therein). However, sperm 
analysis was not available in any of these cases making 
impossible to ascertain if these men had also normal 
spermatogenesis. About 10% of “fertile” men are severe 
oligospermic (62), therefore fertility is not a synonym of 
normozoospermia. Despite this concept, most studies used 
“proven fertile men” with unknown sperm count, as a 
control group rather than a group of “normospermic men”. 
Thus the fertile men with deletions may themselves have 
been oligozoospermic or these deletions may be rare 
polymorphic variants (63,64) or related to technical errors. 
Natural transmission of deletions removing the entire AZFc 
deletions has been also reported (1, 65, 66, 67), but sperm 
analysis was available only in two cases. Two fathers (one 
with reduced sperm count) were able to father only one 
child (1, 65) whereas the father of four infertile sons was 
azoospermic many years later after the natural conception 
of his sons (66). These findings indicate that the natural 
transmission of this genetic defect is likely to be related to 
a situation where the father had oligozoospermia with 
progressive decrease of his sperm count over time 
associated with a high fertility state of the female partner.  
 
To date over 1000 normospermic men have been 
tested in a double blind study (68) and in subsequent 
studies (see 61 and references therein, personal data) and 
no Yq microdeletions have been reported for this category 
of men. It is therefore clear that AZF deletions inevitably 
lead to spermatogenic disturbances of different entity. 
 
8.2. Genotype/phenotype correlations 
Since AZF genes are mainly expressed in the 
testis, a number of studies have been undertaken in order to 
clarify if AZF deletions may cause other testis related 
pathologies than spermatogenic failure. No final evidence 
for a cause–effect relationship with varicocele, 
cryptorchidism, testis cancer have been reported, on the 
contrary, a meta-analysis by Kunej et al. (69) showed that 
the incidence of Yq deletions in cryptorchid men is less 
frequent than in patients with normally descended testis. In 
a group of 437 patients we found a total of 15 AZF 
deletions, 80% of these patients were previously defined as 
idiopathic infertile whereas in a minority of cases other 
abnormal andrological findings such as varicocele, 
cryptorchidism, central hypogonadism, testis trauma etc 
were also present. In order to define if hormone levels may 
be indicative for the presence of Yq deletions, we and 
others performed a complete hormonal analysis in all 
patients screened for Yq deletions. In two studies of the 
Danish population (68, 70) FSH levels in patients with AZF 
deletions were above the mean value in all cases. Serum 
Inhibin B concentrations were uniformly below the normal 
range in each patient. In an other study, testicular endocrine 
function, in a total of 89 oligo-azoospermic patients with 
and without microdeletions, have been evaluated (Tomasi 
personal communication) and Inhibin B and FSH levels 
were undistinguishable in patients with idiopathic and 
microdeletion-associated oligo-azoospermia. These data do 
not support the hypothesis proposed by an other group (71), 
that microdeleted patients have a less severe impairment of 
Sertoli cell function than patients with idiopathic oligo-
azoospermia. The relatively high level of Inhibin B, found 
in the group of men with AZF deletions presenting SCOS 
may be related to overlooking of areas of spermatocytic 
arrest or to a false overrepresentation of SCOS detected by 
fine needle biopsy used by authors (71). 
 
In conclusion, a part from spermatogenic 
disturbance, no specific hormonal alterations or specific 
pathologies have been identified in association with Yq 
deletetions. Since the first description of the three AZF 
regions Vogt et al. (1) suggested that in each subregion the 
deletion is associated with distinct histopathological profile 
and that azoospermia is a constant phenotype in men with 
AZFa and AZFb deletions. This initial genotype-phenotype 
correlation has been questioned by subsequent studies 
reporting the presence of spermatozoa in the ejaculate or in 
the testis in patients with AZFa and AZFb deletions. These 
apparent discrepancies have mainly derived from the 
incorrect use of terminology. A deletion in the AZFa or 
AZFb region or a deletion of the AZFa or AZFb region are 
two different conditions and these two terms were often 
used as interchangeable. The first terminology should be 
used in case the deletion does not remove the entire region 
whereas the second only in case of a complete deletion 
(when it is of the same size described by Vogt et al. 1). 
Deletions removing the entire AZFa or AZFb regions 
(“complete” deletions) are associated with Sertoli Cell 
Only Syndrome (SCOS) and spermatogenic arrest, 
respectively (72,73). On the contrary, such a strict 
genotype/phenotype correlation is lacking for the partial 
deletions of these regions or for the AZFc deletions which 
are associated with a variable phenotype ranging from 
hypospermatogenesis (oligozoospermia) to SCOS 
(azoospermia). A possible explanation for such a variable 
phenotype is a progressive regression of the germinal 
epithelium (74, 75) or a progressive decrease of sperm 
number over time (76, 77, 78). An alternative explanation 
for the variable phenotype can be related to influences of 
the genetic background (compensation for the absence of 
Yq genes, by autosomal or X-linked factors), the presence 
of 45X lines (79) and environmental factors in different 
individuals. 
 
8. 3. Incidence of AZF and AZF gene specific deletions. 
Indications for screening. 
The initial large variability of deletion 
frequencies reported in the previous review in 1999 was 
more likely the consequence of technical problems and the 
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use of unreliable markers rather than an expression of true 
ethnic differences. With time, after having  improved the 
detection method this figure became more homogeneous. 
Although the composition of the study population is 
certainly the major factor influencing deletion frequency, 
the originally reported 55% of deletion frequency in 
patients affected by SCOS was clearly an overestimation 
and was not confirmed by later studies (6).We studied 4 
different populations (three of European and one of non-
European origin) with a similar set of primers and using 
homogeneous criteria for the definition of “idiopathic” and 
“non-idiopathic” infertility (68, 80, 81 and personal data). 
The deletion frequency calculated for the overall study 
population of each study ranged from 1.5% to 10.8%. The 
highest frequencies were found in two studies with the 
largest number of azoospermic men included. The 
calculation of deletion frequency for uniformly defined 
group of idiopathic severe oligo- and azoospermic men 
showed a more homogeneous figure, of 10-18% which 
suggest that ethnic or geographic differences apparently 
have no influence on deletion frequency. The highest 
incidence, 15% was found in idiopathic azoospermic men 
whereas in the group of severe oligospermic patients it 
drops to 5-7%.  
 
Despite the effort of many laboratories, isolated 
AZF gene deletions have been reported only sporadically 
therefore they must be extremely rare.  Interestingly, a 
group (53) have reported a surprisingly high number of 
isolated gene-specific deletions within the AZFa region in a 
relatively small series of patients. This finding has not been 
confirmed in more than 1300 infertile males tested for 
AZFa genes by different groups (52, 68, 70, 80, 81). 
Considering that no specific phenotype has been reported 
for patients bearing “isolated gene” deletions, it is unlikely 
that the lack of isolated gene deletions in the other studies 
is related to patient selection criteria. In our own cohort of 
patients from the Florence area we tested a total 800 men 
for the following AZF genes: USP9Y and DBY (AZFa); 
HSFY and eIF-1AY (AZFb). So far we found one patient 
with a partial deletion of the USP9Y gene (82 submitted). 
Recently a deletion removing one AZFb gene, the HSFY 
(54), has been reported in an azoospermic man, but in 
analogy to the majority of isolated AZFa gene deletions, 
the molecular definition of the deletion is incomplete and 
rearrangements influencing PCR based detection has not 
been ruled out.  
 
As far as the AZF deletions are concerned, it can 
be now concluded that: i)Y deletions have been found 
almost exclusively in patients with <1 millions 
spermatozoa/ml; ii) deletions are extremely rare with a 
sperm concentration >5 millions of spermatozoa/ml 
(approximately 0.7%) and in certain cases deletions 
removed only single STSs which without further 
confirmation by other techniques, such as Southern blotting 
or breakpoint definition, are of dubious significance; iii) the 
most frequently deleted region is AZFc (approximately 
60%), followed by deletions of the AZFb and AZFb+c or 
AZFa+b+c regions (35 %) whereas deletions of the AZFa 
region are extremely rare (5%). Indications for screening 
AZF deletions are azoospermia and severe oligozoospermia 
(<5 million spermatozoa/ml). Since isolated gene specific 
deletions are extremely rare there is no absolute 
requirement for gene specific deletion screening. The EAA 
guidelines provides a set of primers (two markers for each 
region) which is able to detect over 95% of clinically 
relevant deletions (6).  
 
8. 4. Yq deletions and genetic counselling. 
A part from a few inherited cases, the majority of 
Yq deletions occur as de novo events. While the 
mechanism of Y chromosome deletions is now understood, 
their cellular origin is still unclear. A testicular origin 
(during meiosis) seems the most likely although deletions 
could arise in fertilised eggs or embryos. The natural 
transmission of AZFc and partial AZFb deletions indicates that 
the absence of gene products removed by these types of 
deletions does not preclude sperm fertilizing ability. For the 
moment the only effective treatment for these patients is IVF 
(in vitro fertilization with embryo transfer) or ICSI 
(IntraCytoplasmic Sperm Injection) depending on the quantity 
of ejaculated spermatozoa. Due to discordances in the 
literature, it is not clear if the fertilization rate and embryo 
development are comparable to that observed in men without 
deletions (83, 84, 85, 86, 87). 
 
The screening for Yq deletions is of additional 
clinical utility in azoospermic men in which the type of 
deletion may have prognostic value for testicular sperm 
retrieval. Testicular sperm extraction (TESE) is not 
recommended in case of complete AZFa or AZFb deletions 
since the probability of the presence of mature sperm is 
virtually zero. Although the question about a progressive 
decrease of sperm production leading to azoospermia is 
debated (for review see 88 and references therein, 89) 
cryoconservation of sperm can be advised as a preventive 
therapy since it is a non-invasive procedure.  
 
After conception, Y deletion is obligatory 
transmitted to the male offspring therefore genetic 
counselling is mandatory. The phenotype of son may vary 
substantially and the extent of spermatogenic failure cannot 
be predicted entirely due to different genetic background 
and the presence or absence of environmental factors with 
potential toxicity to reproductive function.  
 
We and others have reported that a significant 
proportion of spermatozoa from men with Y microdeletion are 
nullisomic for sex chromosomes (79, 90). This result indicates 
a potential risk for the offspring to develop 45,X0 Turner’s 
syndrome and other phenotypic anomalies associated with sex 
chromosome mosaicism, including ambiguous genitalia. The 
screening for Y chromosome microdeletions in patients 
bearing a mosaic 46XY/45X0 karyotype with sexual 
ambiguity and/or Turner stigmata has shown a relatively high 
incidence of AZFc deletions (33%; 91). Additional data (79, 
92, 93) support that Yq microdeletions could be associated 
with an overall Y chromosomal instability leading to the 
formation of 45,X0 cell lines.  
 
Despite this theoretical risk, the 36 babies (18 
male and 18 female) born from fathers affected by Yq 
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microdeletions are phenotypically normal (for references 
see 88). This could be due to the reduced implantation rate 
and a likely higher risk of spontaneous abortions of 
embryos bearing a 45,X0 karyotype.  
 
In order to avoid the transfer of embryos with sex 
chromosome mosaicism, preimplantation diagnosis could 
be offered to the couple. This analysis, together with the 
abortion rate would provide a more realistic estimation 
about the real risks of 46, XY/45,X0 mosaicism and Turner 
syndrome. 
 
9. CONCLUSIONS AND PERSPECTIVES 
 
As we already suggested in 1999, the 
identification of Y deletions has a diagnostic, prognostic 
and preventive value. The diagnosis provides the cause of 
the spermatogenic failure and thus it avoids unnecessary 
medical (hormonal and non hormonal) and surgical 
(varicocele operations) treatments. In azoospermic men, the 
presence of a complete AZFa or AZFb deletion has a 
negative prognostic value for testicular sperm retrieval (73, 
94, 95 and Silber personal comunication). In patients 
presenting oligozoospermia who are at risk for a 
progressive decrease of sperm concentration over time, 
cryoconservation of spermatozoa could avoid future more 
invasive techniques such as TESE/ICSI. The same 
preventive therapy may be proposed to affected sons (2).  
 
A part from the classical AZF deletions, a new 
type of Yq deletion has recently attracted the attention of 
geneticist and andrologist. A partial deletion in the AZFc 
region, termed “gr/gr” has been described specifically in 
infertile men with varying degrees of spermatogenic failure 
(8, 96). This deletion removes half the AZFc gene content 
including two copies of the major AZFc candidate gene 
called DAZ (34). As it happens in the late 90thies for the 
classical AZF deletions, we are now facing to an intensive 
search for gr/gr deletions in infertile and control 
normospermic men in order to define their frequency and 
clinical significance (97, 98, 99, 100, 101). From the first 
studies it is already clear that in contrast to the classical 
AZF deletions, “gr/gr” deletions can be found also in 
normospermic men (98,100,101) although at a significantly 
lower frequency. Therefore, rather than a specific cause, 
this genetic anomaly represents a risk factor for 
spermatogenic failure. Among a number of plausible 
explanations for the heterogeneous phenotype we 
hypothesized the presence of polymorphisms or mutations 
in the autosomal homologue of the DAZ gene, DAZL (41). 
However, similarly to the AZFc deleted patients, we found 
no new mutations in the entire coding region of the DAZL 
gene and the polymorphic Thr12-Ala change (T12A), due 
to its relatively high frequency in the normospermic group, 
does not seem to have any modulating effect (101, 102). 
The currently used method for the detection of gr/gr 
deletions is based on STS plus/minus type of analysis 
which  alone does not provide information about the type of 
missing gene copies. This analysis may also detect false 
deletions due to rearrangements of the STS containing 
sequence and is also unable to rule out a duplication of the 
non-deleted part of the AZFc region. The majority of 
“gr/gr” studies are lacking of a detailed molecular analysis 
i.e. the reduced gene dosage is not confirmed and the type 
of deleted gene copies is also unknown (98, 99, 99, 100). 
Mitchell and coworkers (97) have developed a method able 
to detect the type of the missing CDY and DAZ copies 
whereas Vogt and co-workers (103) developed an RFLP 
based DAZ copy analysis. Our preliminary data indicate 
that gr/gr deletions associated with the loss of CDY1a copy 
is found only in infertile men and not in normospermic 
control (101). However, the number of controls with gr/gr 
deletion is low and further combined studies are needed to 
confirm this preliminary result.  
 
Besides the gr/gr deletions the AZFc region 
predisposes to a number of other possible partial deletions 
(9, 104). The Y chromosome background seems to play an 
important role in the pathogenic consequence of these 
deletions: for example another deletion named “b2/b3” 
(106) or “u3-gr/gr” (97) or “g1/g3” (107), which removes a 
similar quantity of AZFc genes than the gr/gr deletion, 
seems to have no effect on fertility status in association 
with a certain Y chromosome background commonly 
present in Northern Eurasian populations (Y haplogroup N) 
(106,107). A similar conclusion can also be drawn for the 
“gr/gr” deletion found in association with Hgr D2b which 
is present in 20% of Japanese men. Consequently, a 
combined molecular characterization (haplogroup, gene 
dosage, and gene copy type definition) of the “gr/gr” 
deleted patients and controls will probably allow the 
distinction between pathogenic and neutral deletions. In the 
meantime, the screening for “gr/gr” deletions maybe 
advised to patients attending for assisted reproductive 
techniques, since this test will provide the identification of 
a transmissible genetic risk factor for reduced sperm count.  
 
In contrast to the advancement in the clinical 
aspects of AZF deletions, many fundamental questions 
concerning the function of AZF genes remains to be 
answered. The largely unsuccessful search for gene specific 
deletions/mutations did not allow to obtain  information 
through genotype-phenotype correlation therefore future 
expression studies are needed to get insight into gene 
function. Partial AZFc deletions are promising new area of 
research which may lead to the identification of a new 
genetic cause (and not “only” a risk factor) of 
spermatogenic disturbance.    
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